Abstract:Whole brain radiation therapy (WBRT) remains the standard treatment of brain metastasis (BM) from breast cancer (BC), especially in patients (pts) with multiple lesions. Post-WBRT anti-HER 2 treatment has been reported to improve overall survival (OS) in pts with BM from HER 2+ BC. Nevertheless, whether the benefit of post-WBRT anti-HER 2 treatment varies with prior targeted therapy is unclear. Current study aims to explore the benefit of post-WBRT anti-HER 2 treatment with regards to prior status of targeted therapy. A total of 60 pts with BM from HER 2-+ BC treated with WBRT in single institute between Jan.2006 and Feb.2012 was retrospectively analyzed, 46 pts (76.7%) had multiple lesions. The median age at BM was 53 yrs (28-73 yrs). The brain was the first metastatic site in 16 pts (26.7%). Post-WBRT anti-HER 2 treatment was given to 40.0% (n = 24) of pts, 19 of them also had anti-HER 2 therapy prior to BM, in the adjuvant (n = 7) and/or metastatic setting (n = 16). Prognostic analysis was performed including age at BM, KPS/RPA, ER/PR status, number of BM, interval between BC diagnosis and BM, presence of extracranial metastases, extracranial metastases control, chemotherapy after WBRT and anti-HER 2 treatment after WBRT. The median OS after BM in the whole group was 12 months (1-94 m). In univariate analysis, age, KPS/RPA classes, number of BM, extracranial metastases control, chemotherapy after WBRT and anti-HER 2 treatment after WBRT were significant prognostic factors for OS (p < 0.05), while in multivariate analysis, extracranial control, chemotherapy after WBRT and anti-HER 2 treatment after WBRT were significant prognostic factors for OS. OS was significantly longer in pts who received anti-HER 2 treatment after WBRT compared with pts who did not (21 vs 9 m; p = 0.002), which was also significantly longer in pts received chemotherapy after WBRT than those who did not (16 vs 6 m; p < 0.001). The best median survival (34 m) was observed in pts who started anti-HER 2 treatment ONLY after WBRT, followed by pts (18 m) who had anti-HER 2 treatment before and after WBRT, and pts without anti-HER 2 treatment at all (9 m) (p = 0.002). The median interval from diagnosis of BC to BM was 29.5 m (2-136 m) in the whole cohort, which was longer in pts receiving anti-HER 2 treatment before BM (51 m) compared with those did not (27 m), with marginal statistical significance (p = 0.06). Both anti-HER 2 treatment and chemotherapy after WBRT prolonged OS in HER 2 + breast cancer pts with BM. The greatest survival benefit from anti-HER 2 treatment was observed in pts who had anti-HER 2 treatment only after WBRT. Prior anti-HER 2 therapy in the adjuvant or metastatic setting seemed to prolong the interval from diagnosis of BC to the development of BM.

Outcome of Brain Metastases from HER 2–positive Breast Cancer: Difference in Survival Benefit from Anti-HER 2 Treatment after WBRT with Regard to Prior Targeted Therapy